Pfizer Faces 3 Class Actions Over Generic Delay Scheme
Pfizer Inc. has been hit with three class actions alleging it improperly obtained a patent from the U.S. Patent and Trademark Office for its arthritis drug Celebrex and used it to...To view the full article, register now.
Already a subscriber? Click here to view full article